Коронавирус 2020
Россияне сплагиатили и выпустили непроверенным?
This COVID-19 vaccine candidate from Russia joins two other adenovirus-vectored COVID-19 vaccine candidates, which have been reported in randomised trials in The Lancet,2, 3 and an mRNA vaccine candidate reported in a non-randomised trial.4 Similar to these studies before it, Logunov and colleagues’ studies are encouraging but small. The immunogenicity bodes well, although nothing can be inferred on immunogenicity in older age groups, and clinical efficacy for any COVID-19 vaccine has not yet been shown. A wide portfolio of early COVID-19 vaccine candidates will hopefully provide more successful vaccines that are broadly protective across risk groups and that increase the global availability of what will be a precious limited commodity.